Bionano Genomics announces presence at upcoming cytogenetics conferences

Bionano Genomics announced the Company’s robust participation at two upcoming cytogenetics conferences, the 2024 European Society for Human Genetics Annual Conference and the 2024 American Cytogenomics Conference, with a record 39 scientific presentations and posters across the two conferences that highlight the utility of the Company’s OGM workflow for applications in genetic disease, cancer, and rare disease research and discussing the latest advances to the Company’s suite of products, including the high throughput Stratys system and VIA software. ESHG brings together industry and academic professionals annually to discuss new technologies and advances in the field of human genetics. ESHG sessions will take place June 1-4, 2024 virtually and in Berlin, Germany. ACC is a biennial conference focused on new technologies and advances in the field of cytogenetics. ACC will be held June 2-5, 2024 in Norfolk, Virginia. Bionano will host a sponsored session at ESHG featuring an overview of the Company’s OGM workflow delivered by Bionano’s chief medical officer, Dr. Alka Chaubey, a presentation from Dr. Laura Batlle Maso at Vall d’Hebron Institute of Research on OGM’s potential utility in resolving hereditary angioedema cases, a presentation from Dr. Bart van der Sanden at Radboud UMC covering how OGM may be useful for the detection of SVs relevant to rare disease, and a presentation from Marlene Ek at Karolinska Institute highlighting OGM’s ability to unveil more cytogenomic insights into multiple myeloma samples than traditional cytogenetic methods. At ACC, a sponsored session will feature Dr. Mike Gallagher, market development manager at Bionano, highlighting OGM’s ability to enhance detection of pathogenic variants and to advance genetic disease research. Dr. Gallagher will also introduce the latest innovations in the OGM workflow, including the Stratys system and VIA software.